8-K: Waystar Reports Strong Q4, FY25 Results; Boosts 2026 Outlook

Waystar Holding Corp. announced robust fourth-quarter and full-year 2025 financial results, driven by significant revenue growth and strong profitability, alongside optimistic 2026 guidance.

Summary

• Fourth quarter 2025 revenue reached $303.5 million, marking a 24% increase year-over-year.
• Net income for Q4 2025 was $20.0 million, with a net income margin of 7%.
• Non-GAAP net income for Q4 2025 stood at $70.7 million.
• Adjusted EBITDA for Q4 2025 was $129.1 million, achieving an adjusted EBITDA margin of 43%.
• Full fiscal year 2025 revenue totaled $1,099.3 million, an increase of 17% year-over-year.
• Net income for FY 2025 was $112.1 million, with a net income margin of 10%.
• Non-GAAP net income for FY 2025 was $262.9 million.
• Adjusted EBITDA for FY 2025 reached $462.1 million, with an adjusted EBITDA margin of 42%.
• 1,391 clients contributed over $100,000 in last twelve months (LTM) revenue, up 16% year-over-year.
• The Net Revenue Retention Rate (NRR) was 112%.
• Fourth quarter 2025 subscription revenue grew 38% year-over-year to $167.8 million.
• Fourth quarter 2025 volume-based revenue increased 11% year-over-year to $134.2 million.
• Fiscal year 2025 subscription revenue grew 22% year-over-year to $558.4 million.
• Fiscal year 2025 volume-based revenue increased 11% year-over-year to $534.8 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong financial performance, successful strategic execution (Iodine acquisition, AI innovation), and optimistic forward-looking guidance, indicating continued growth potential in the healthcare payment software market.

Positives

• Strong revenue growth: Q4 2025 revenue increased by 24% year-over-year, and full-year 2025 revenue increased by 17% year-over-year.
• High adjusted EBITDA margins: 43% in Q4 2025 and 42% for the full fiscal year 2025, demonstrating efficient operations.
• Significant increase in high-value clients: 1,391 clients contributed over $100,000 in LTM revenue, representing a 16% year-over-year increase.
• Healthy Net Revenue Retention Rate (NRR) of 112%, indicating strong customer satisfaction and expansion within the existing client base.
• Robust subscription revenue growth: Q4 2025 subscription revenue was up 38% year-over-year, and FY 2025 subscription revenue was up 22% year-over-year.
• Successful integration of the Iodine acquisition ahead of plan, enhancing platform capabilities.
• Accelerating AI-powered innovation across the platform, positioning the company as a leader in healthcare's AI transformation.
• Optimistic 2026 guidance reflecting a robust pipeline and accelerating demand for an end-to-end AI-powered platform, signaling continued durable, profitable growth.

Negatives

• GAAP net income margins (7% in Q4 2025 and 10% in FY 2025) are substantially lower than adjusted EBITDA margins, highlighting significant non-GAAP adjustments.
• Cash and cash equivalents decreased from $182,133 thousand at December 31, 2024, to $61,355 thousand at December 31, 2025.
• Net debt increased from $1,061,413 thousand at December 31, 2024, to $1,395,014 thousand at December 31, 2025.
• The adjusted net leverage ratio increased from 2.8x at December 31, 2024, to 3.0x at December 31, 2025.

Risks

• Operating in a highly competitive industry.
• Ability to retain existing clients and attract new clients.
• Ability to successfully execute on business strategies to grow.
• Ability to accurately assess risks related to acquisitions and successfully integrate acquired businesses, including Iodine.
• Ability to establish and maintain strategic relationships.
• Growth and success of clients and overall healthcare transaction volumes.
• Consolidation in the healthcare industry.
• Selling cycle of variable length to secure new client agreements.
• Implementation cycle dependent on client timing and resources.
• Dependence on senior management team and certain key employees, and ability to attract and retain highly skilled employees.
• Accuracy of the estimates and assumptions used to determine the size of the total addressable market.
• Ability to develop and market new solutions, or enhance existing solutions, to respond to technological changes or evolving industry standards.
• Interoperability, connectivity, and integration of solutions with clients' and their vendors' networks and infrastructures.
• Performance and reliability of internet, mobile, and other infrastructure.
• Consequences if highly regulated data required to provide solutions cannot be obtained, processed, used, disclosed, or distributed.
• Reliance on certain third-party vendors and providers.
• Any errors or malfunctions in products and solutions.
• Failure by clients to obtain proper permissions or provide accurate and appropriate information.
• Potential for embezzlement, identity theft, or other similar illegal behavior by employees or vendors, and a failure of employees or vendors to observe quality standards or adhere to environmental, social, and governance standards.
• Compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks.
• Increases in card network fees and other changes to fee arrangements.
• Effect of payer and provider conduct which cannot be controlled.
• Privacy concerns and security breaches or incidents relating to the platform or data (including personal information and other regulated data).
• Complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity.
• Ability to adequately protect and enforce intellectual property rights.
• Ability to use or license data and integrate third-party technologies.
• The development, deployment, and use of AI.
• Use of open source software.
• Legal proceedings initiated by third parties alleging infringement or other violation of their intellectual property rights.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• The heavily regulated industry in which business is conducted.
• The uncertain and evolving healthcare regulatory and political framework.
• Health care laws and data privacy and security laws and regulations governing the processing of personal information.
• Reduced revenues in response to changes to the healthcare regulatory landscape.
• Legal, regulatory, and other proceedings that could result in adverse outcomes.
• Contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act/anti-money laundering laws and regulations.
• Existing laws that regulate the ability to engage in certain marketing activities.
• Full compliance with website accessibility standards.
• Any changes in tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities.
• Limitations on the ability to use net operating losses to offset future taxable income.
• Losses due to asset impairment charges.
• Substantial debt and restrictive covenants in the agreements governing Credit Facilities.
• Interest rate fluctuations.
• Unavailability of additional capital on acceptable terms or at all.
• The impact of general macroeconomic conditions.
• History of net losses and ability to achieve or maintain profitability.
• The interests of certain investors may be different than the interests of other holders of securities.

Future Outlook

Waystar projects full fiscal year 2026 total revenue between $1.274 billion and $1.294 billion, adjusted EBITDA between $530 million and $540 million, non-GAAP net income between $317 million and $335 million, and diluted non-GAAP net income per share between $1.59 and $1.68. This guidance reflects a robust pipeline, accelerating demand for an end-to-end AI-powered platform, and disciplined execution to sustain durable, profitable growth.

Management Comments

• "Waystar is delivering strong growth and momentum—driving record bookings, integrating the Iodine acquisition ahead of plan, and accelerating AI-powered innovation across our platform."
• "We are leading healthcare's AI transformation by advancing the autonomous revenue cycle, leveraging unmatched proprietary data and deep domain expertise to deliver meaningful outcomes for providers."
• "Our 2026 guidance reflects a robust pipeline, accelerating demand for an end-to-end AI-powered platform, and disciplined execution to sustain durable, profitable growth."

Industry Context

StockSavvy.ai notes that Waystar's strong performance, particularly in subscription revenue growth and AI-powered innovation, aligns with the broader trend of digital transformation and automation in the healthcare sector. The focus on an "autonomous revenue cycle" positions Waystar to capitalize on increasing demand for efficiency and cost reduction among healthcare providers, a critical need in a complex and evolving industry landscape. The successful integration of the Iodine acquisition further strengthens its competitive position against other healthcare technology providers.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark Waystar's performance against. Therefore, a direct comparison to industry standards with specific examples is not possible based solely on the provided text.

Stakeholder Impact

• Shareholders: Positive financial results, strong growth, and optimistic guidance are likely to be favorable, potentially leading to increased shareholder value.
• Customers (Providers): Continued investment in AI-powered innovation and an "autonomous revenue cycle" suggests enhanced software solutions, which could lead to improved financial performance and simplified payment processes for healthcare providers.
• Employees: Strong company performance and growth could lead to job stability, potential career advancement opportunities, and increased morale, particularly in areas of AI development and integration.
• Creditors: While net debt and the adjusted net leverage ratio increased, strong adjusted EBITDA and cash flow generation provide a solid basis for debt servicing, offering comfort to creditors.

Next Steps

• A conference call to discuss financial results is scheduled for February 17, 2026, at 8:30 a.m. Eastern Standard Time.
• A live audio webcast of the conference call will be available on Waystar's website, with an archived version accessible for later listening.
• The company routinely posts important information, including corporate and investor presentations and financial information, on the Investor Relations section of its website.
• Investors should monitor the Investor Relations section of the website for material, non-public information and compliance with Regulation FD.

Key Dates

Recommendation

The company demonstrates robust financial performance with significant year-over-year revenue growth and healthy adjusted EBITDA margins. The successful integration of a key acquisition and acceleration in AI-powered innovation highlight strong strategic execution. Furthermore, the optimistic 2026 guidance, coupled with a solid net revenue retention rate, indicates sustained momentum and future profitability, making it an attractive investment.

Keywords

Healthcare Payment Software, Revenue Cycle Management, AI Transformation, Financial Results, Earnings, Q4 2025, FY 2025, 2026 Guidance, Waystar, Iodine Acquisition, Adjusted EBITDA, Net Revenue Retention, Subscription Revenue